<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00612079</url>
  </required_header>
  <id_info>
    <org_study_id>97_PPI-P50</org_study_id>
    <secondary_id>E-07/2007</secondary_id>
    <secondary_id>2007DR1251</secondary_id>
    <nct_id>NCT00612079</nct_id>
  </id_info>
  <brief_title>The Effect of Sertindole on Sensory Gating and Cognition in Healthy Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Psychiatric University Hospital, Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to further validate and extend our previous findings insofar that the effect
      of the atypical antipsychotic and mixed 5-HT2/D2 antagonist sertindole on sensorimotor gating
      processes and its relationship to cognitive performance shall be explored.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensory (EEG: P50 suppression) and sensorimotor gating (EMG: PPI)</measure>
    <time_frame>after placebo and and after medical treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive performances</measure>
    <time_frame>after placebo and and after medical treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers with high sensory gating levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers with low sensory gating levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertindole</intervention_name>
    <description>oral 3 x 4mg</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 x 4mg Placebo</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-40

          -  Gender: male

        Exclusion Criteria:

          -  Axis I Disorders: lifetime DSM IV diagnosis according to DIA-X of alcohol or illicit
             drug dependence. No life-time DSM IV diagnosis according to DIA-X of a major
             affective, psychotic, anxiety disorder, eating-disorder as defined above.

          -  Axis II Disorders: lifetime DSM IV diagnosis of personality disorder according to
             SCID-II.

          -  Family history: lifetime history of 1st degree relative (parents and siblings) of a
             major affective, psychotic, or anxiety disorder as defined above.

          -  ECG: QTc-interval &gt;450 msec.

          -  Systolic blood pressure &lt;100 mmHg

          -  Bradycardia (Hf &lt; 50/Min) und Arrhythmias

          -  Hypokalemia or Hypomagnesemia
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franz X. Vollenweider, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Psychiatry, Department Neuropsychopharmacology and Brain Imaging</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Psychiatry Hospital</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>CH-8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Holstein DH, Csomor PA, Geyer MA, Huber T, Brugger N, Studerus E, Vollenweider FX. The effects of sertindole on sensory gating, sensorimotor gating, and cognition in healthy volunteers. J Psychopharmacol. 2011 Dec;25(12):1600-13. doi: 10.1177/0269881111415734. Epub 2011 Sep 2.</citation>
    <PMID>21890590</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2008</study_first_submitted>
  <study_first_submitted_qc>February 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2008</study_first_posted>
  <last_update_submitted>September 14, 2012</last_update_submitted>
  <last_update_submitted_qc>September 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sertindole</keyword>
  <keyword>sensory gating</keyword>
  <keyword>PPI</keyword>
  <keyword>P50 suppression</keyword>
  <keyword>CANTAB</keyword>
  <keyword>Effect of Sertindole on sensory gating (P50 suppression)</keyword>
  <keyword>on sensorimotor gating (PPI)</keyword>
  <keyword>and cognition (CANTAB)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertindole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

